Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/234726COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES
WO 26.11.2020
Int.Class A61K 31/454
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Appl.No PCT/IB2020/054637 Applicant PFIZER INC. Inventor ASPNES, Gary E.
In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.
2.WO/2020/236626METHODS AND SYSTEMS FOR TREATING MICROBIAL DISEASE
WO 26.11.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/033210 Applicant HERZLINGER, George A. Inventor HERZLINGER, George A.
The present disclosure provides methods and systems for treating a biological fluid of a subject suffering from a microbial infection (e.g., a drug-resistant microbial infection). In some embodiments, these methods and systems involve a complement receptor immobilized on, or otherwise associated with a polymer substrate, for example, high surface area particles, membranes, hollow fibers, and/or other porous or non-porous media. In other embodiments, the methods and systems involve a complement receptor present in a dialysate used in a dialyzer for extracting pathogens out of a biological fluid, for example, the blood of a patient.
3.WO/2020/236736TREATMENT OF SYSTOLIC DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION WITH THE COMPOUND(R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUOROETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE
WO 26.11.2020
Int.Class A61K 31/454
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Appl.No PCT/US2020/033438 Applicant MYOKARDIA, INC. Inventor TAMBY, Jean-Francois
Provided herein are methods, use, and compositions for treating systolic dysfunction such as heart failure with reduced ejection fraction.
4.WO/2020/237096COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT
WO 26.11.2020
Int.Class A61K 31/4725
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
472Non-condensed isoquinolines, e.g. papaverine
4725containing further heterocyclic rings
Appl.No PCT/US2020/034090 Applicant ARDELYX, INC. Inventor KING, Andrew
The present invention relates to methods for lowering serum phosphate in a mammal comprising administering an epithelial phosphate transport inhibitor, such as an NHE3 inhibitor, in combination with a phosphate binder as well as pharmaceutical compositions comprising such epithelial phosphate transport inhibitors and phosphate binders.
5.WO/2020/233645MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
WO 26.11.2020
Int.Class C07D 498/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
22in which the condensed system contains four or more hetero rings
Appl.No PCT/CN2020/091434 Applicant ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. Inventor CHEN, Youxi
Provided are macrolide derivatives represented by the formula (I), a preparation method thereof, and an application of the macrolide derivatives as one or more protein kinase inhibitors in TRK, ALK, and ROS1.
6.WO/2020/234355DIETARY BUTYRATE
WO 26.11.2020
Int.Class A23L 33/135
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
135Bacteria or derivatives thereof, e.g. probiotics
Appl.No PCT/EP2020/064080 Applicant SOCIÉTÉ DES PRODUITS NESTLÉ S.A. Inventor PATIN, Amaury
Use of a compound having the formula (1) (2) (3) or (4) or combinations thereof, for increasing blood ketone levels, and/or treating a disease treatable by increasing blood ketone levels, preferably wherein the disease is selected from the list consisting of: a brain energy deficiency condition, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, inherited metabolic disorders (such as glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase complex deficiency), depression, schizophrenia, epilepsy, narcolepsy, diabetes, obesity, non-alcoholic fatty liver disease and polycystic ovary syndrome, wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.
7.WO/2020/234424BENZO[C][1,2,5]OXADIAZOLE FOR THE TREATMENT OF DISEASES CAUSED BY HELICOBACTER
WO 26.11.2020
Int.Class A61K 31/4245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4245Oxadiazoles
Appl.No PCT/EP2020/064214 Applicant UNIVERSIDAD DE ZARAGOZA Inventor SANCHO SANZ, Javier
The present invention relates to new compounds which are benzo[c][1,2,5]oxadiazole derivatives, and the use thereof in the treatment of infectious diseases caused by Helicobacter pylori. Also, the present invention relates to a pharmaceutical composition and to a combined preparation both comprising said compounds
8.WO/2020/234454COMBINATION TREATMENT OF CANCER TARGETING ENERGY METABOLISM AND INTRACELLULAR PH
WO 26.11.2020
Int.Class A61K 31/155
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
155Amidines , e.g. guanidine , isourea , isothiourea
Appl.No PCT/EP2020/064281 Applicant DEUTSCHES KREBSFORSCHUNGSZENTRUM Inventor MELNIK, Svitlana
The present invention relates to a compound causing a decrease of intracellular pH for use in treatment of cancer with an inhibitor of mitochondrial respiration and a proton ionophore; to a proton ionophore for use in treatment of cancer with an inhibitor of mitochondrial respiration and a compound causing a decrease of intracellular pH; and to an inhibitor of mitochondrial respiration for use in treatment of cancer with a proton ionophore and a compound causing a decrease of intracellular pH. The present invention also relates to a combined preparation for simultaneous, separate or sequential use comprising (i) a compound causing a decrease of intracellular pH, (ii) an inhibitor of mitochondrial respiration, and (iii) a proton ionophore, and to a method for determining whether a subject suffering from cancer is susceptible to a combined treatment comprising administration of a compound causing a decrease of intracellular pH, an inhibitor of mitochondrial respiration, and a proton ionophore related thereto.
9.WO/2020/235973NOVEL USE OF PYRROLO-PYRIDINE DERIVATIVE COMPOUND FOR PREVENTION AND/OR TREATMENT OF CANCER
WO 26.11.2020
Int.Class A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
Appl.No PCT/KR2020/006730 Applicant VORONOI CO., LTD. Inventor AHN, Jae Young
The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, comprising an anticancer drug and a pyrrolo-pyridine derivative compound as an active ingredient. A compound represented by chemical formula 1 according to the present invention, an isomer thereof, or a pharmaceutically acceptable salt thereof has excellent inhibitory activity against protein kinases, and thus, when used in combination with other anticancer drugs, can be effectively used in the prevention, treatment, or amelioration of cancer.
10.WO/2020/237043HUMAN TACTILE PREPULSE INHIBITION ASSAY
WO 26.11.2020
Int.Class A61K 31/445
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
Appl.No PCT/US2020/033984 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor GINTY, David, D.
In some aspects, the disclosure relates to a prepulse inhibition (PPI) assay comprising the steps of, administering a tactile prepulse to a human subject, administering a startle stimulus to the subject, and measuring the subject's response to the startle stimulus. In another aspect, the disclosure relates to a method for evaluating tactile hypersensitivity and/or sensorimotor impairment in a human subject, comprising, administering to the subject a PPI assay according to any one of the preceding claims, comparing the assay results to neuro-typical controls, and determining the degree of tactile hypersensitivity and/or sensorimotor impairment in the subject.